Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Redwire Corporation (RDW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Redwire Corporation — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.04B), while Redwire Corporation trades at $9.96 (market cap $2.33B). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is far larger — about 3.5× Redwire Corporation's market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, Redwire Corporation nearer its low. Which is the better fit depends on your goals.
| BIO | RDW | |
|---|---|---|
Market Cap | $8.04B | $2.33B |
Sector | Health | Technology |
52-Week High | $339.75 | $25.90 |
52-Week Low | $241.71 | $5.06 |
Enterprise Value | $7.85B | $2.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
RDW trades at $9.59, down 5.8% with bearish technical signals despite 80% analyst buy ratings. The company shows significant revenue growth but deep losses, with net income margin at -80.9% and negative cash flow from operations. Recent news highlights dilution concerns from a $500M stock offering and competitive pressure from SpaceX's market dominance.
The stock presents high-risk potential with analyst consensus target of $19.00 representing 98% upside, but requires improved profitability and reduced cash burn. Key risks include persistent losses, dilution from financing activities, and intense space sector competition that could limit near-term recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Redwire Corporation
Redwire Corporation is a pure-play space infrastructure company that provides a wide range of advanced solutions for the next generation of space exploration and utilization. The company's capabilities span critical space technology, including on-orbit servicing, satellite components, space robotics, and digital engineering. Redwire's products and services are used by civil, commercial, and national security customers to enable missions from low Earth orbit to deep space.
Read more on RDW →
